Cerca Magnetics Raises €4.3M Series A Funding Led by Guinness Ventures

Why It Matters

The infusion accelerates deployment of quantum‑sensing neuroimaging, lowering barriers to early diagnosis of epilepsy, MS and dementia and challenging incumbent bulky MEG scanners. It also positions Cerca as a potential global leader in next‑generation brain imaging.

Key Takeaways

• Raised €4.3M ($4.75M) Series A at €34.5M valuation.
• Wearable MEG uses optically‑pumped magnetometers for mobile brain scans.
• Enables imaging infants and patients who move, expanding clinical use cases.
• Sold 19 systems in 12 countries, >100% annual sales growth.
• Funding targets regulatory approval, manufacturing scale‑up, and global expansion.

Pulse Analysis

Quantum sensing is reshaping neuroimaging by replacing cryogenic superconducting detectors with room‑temperature optically‑pumped magnetometers. This shift reduces equipment size, cost, and operational complexity, making magnetoencephalography (MEG) feasible outside specialist labs. Cerca Magnetics leverages this technology to create a lightweight, wearable scanner that captures magnetic fields generated by neuronal currents while subjects move naturally, opening new diagnostic pathways for pediatric and movement‑disordered patients.

The recent €4.3 million Series A injection, led by Guinness Ventures, provides the runway needed to navigate stringent regulatory pathways in the UK, EU and United States. With funds earmarked for clinical trials, manufacturing scale‑up, and market expansion, Cerca can transition from a research‑focused supplier to a commercial‑grade device maker. The capital also signals investor confidence in quantum‑based medical devices, a sector still early in its commercialization cycle, and may prompt larger pharmaceutical and imaging firms to consider strategic partnerships or acquisitions.

Clinically, a portable MEG system could democratize access to high‑resolution brain activity mapping, enabling earlier detection of epilepsy foci, monitoring of multiple sclerosis progression, and more precise assessment of dementia biomarkers. Hospitals and research centers worldwide stand to benefit from reduced scan times and the ability to study populations previously excluded from traditional MEG, such as infants or patients unable to stay still. As regulatory approvals materialize and production scales, Cerca’s technology could catalyze a broader shift toward quantum‑enabled diagnostics across neurology and beyond.

Deal Summary

UK MedTech startup Cerca Magnetics announced a €4.3 million ($4.75 million) Series A round at a €34.5 million post‑money valuation. The round was led by Guinness Ventures and will fund clinical expansion, manufacturing scale‑up and international growth of its wearable quantum‑sensing brain imaging systems.